Lampert, Erika J.

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

Lampert, E. J., Zimmer, A., Padget, M., Cimino-Mathews, A., Nair, J. R., Liu, Y., Swisher, E. M., Hodge, J. W., Nixon, A. B., Nichols, E., et al. (2020) · Clinical Cancer Research

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 220

Long-term pelvic organ prolapse recurrence and mesh exposure following sacrocolpopexy

Thomas, T. N., Davidson, E. R. W., Lampert, E. J., Paraiso, M. F. R., & Ferrando, C. A. (2020) · International Urogynecology Journal

Pelvic floor disorders treatmentsUterine Myomas and Treatments

Cited by 31